Cervical cancer is to a large extent a preventable disease, through prophylactic human
papilloma virus (HPV) vaccination and cervical cancer screening. Still, it is the second most …

We aimed to assess the cervical cancer burden and performance of screening programme
over the last decade in Apulia, Italy. Data from Hospital Discharge, Causes of Death and of …

Human papillomavirus (HPV) vaccination within a nonorganized setting creates a poor cost-
effectiveness scenario. However, framed within an organized screening including primary …

Cervical cancer is relatively rare in high‐income countries, where organized screening
programs are in place, as well as opportunistic ones. As the human papillomavirus (HPV) …

Cervical cancer control in the Latin America and Caribbean (LAC) region has been, and
remains, a priority and a major public health challenge. It also provides the opportunity for …

The EUROGIN 2010 roadmap represents a continuing effort to provide and interpret
updated information on cervical cancer screening and vaccination against the cause of the …

Cervical cancer is the fourth most common cancer in women, and the seventh overall, with
an estimated 528,000 new cases and 266,000 deaths in 2012 [1]. Almost nine out of ten …

The EUROGIN 2008 Roadmap represents a continuing effort to provide updated information
on primary and secondary prevention of cervical cancer. The report addresses several areas …

Background Human papillomavirus (HPV) testing for cervical cancer prevention was
introduced in Argentina through the Jujuy Demonstration Project (2011–14). The …

The current incidence of cervical cancer is around 5,300,000 new cases per year worldwide
and mortality 275,000 cases per year. The 80% of these cases are distributed in developing …